Literature DB >> 7693572

Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings.

K Aoki1, K Takayasu, T Kawano, Y Muramatsu, N Moriyama, F Wakao, J Yamamoto, K Shimada, T Takayama, T Kosuge.   

Abstract

Clinicoradiological features were studied in 20 patients with 22 mass lesions of combined hepatocellular carcinoma and cholangiocarcinomas and findings of computed tomography in 12 of these patients with 14 hepatocellular carcinoma-cholangiocarcinomas. Five of these patients also had single overt hepatocellular carcinomas. The incidence of hepatocellular carcinoma-cholangiocarcinoma was 3.3% among the patients with primary liver cancer treated in our hospital. HBsAg was present in 25%, and increased levels of serum alpha-fetoprotein (> 200 ng/ml) and carcinoembryonic antigen (> 5 ng/ml) were found in 25% and in 47%, respectively. Associated cirrhosis was present in 60%. Analysis of 14 hepatocellular carcinoma-cholangiocarcinomas in 12 patients in whom the enhancement pattern on dynamic computed tomography and pathological findings could be studied and compared suggested three tumor types. Nine lesions (type A) were demonstrated only as areas with high-density peripheries in the early phase of enhancement that evolved into a pattern of peripheral low density and central high density in the late phase. Four masses (type B) were shown as hyperdense tumors (early phase) that changed to low density in the late phase. One mass (type C) was seen as a low-density lesion that did not change. Histopathologically, type A comprised hepatocellular carcinoma-predominant components in the peripheral area, cholangiocarcinoma-predominant components with abundant fibrous stroma in the central area and a tissue transitional between the two in the midzone. By contrast, two of four type B masses comprised hepatocellular carcinoma with scattered cholangiocarcinoma components throughout the tumor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693572

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.

Authors:  Dong Ik Cha; Kyung Mi Jang; Seong Hyun Kim; Tae Wook Kang; Kyoung Doo Song
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

Review 2.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

3.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

4.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

5.  Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma.

Authors:  Xiong Cai; Jian Zhai; David E Kaplan; Yijun Zhang; Lining Zhou; Xutao Chen; Guangyang Qian; Qiudong Zhao; Yonghai Li; Lu Gao; Wenming Cong; Minghua Zhu; Zhenlin Yan; Lehua Shi; Dong Wu; Lixin Wei; Feng Shen; Mengchao Wu
Journal:  Hepatology       Date:  2012-06-25       Impact factor: 17.425

6.  Combined hepatocellular and cholangiocarcinoma with sarcomatoid transformation: radiologic-pathologic correlation of a case.

Authors:  Uei Pua; Su-Chong Low; Yu-Meng Tan; Kiat-Hon Lim
Journal:  Hepatol Int       Date:  2009-09-10       Impact factor: 6.047

Review 7.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

8.  Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis.

Authors:  Ka Wing Ma; Kenneth Siu Ho Chok; Wong Hoi She; Tan To Cheung; Albert Chi Yan Chan; Wing Chiu Dai; James Yan Yue Fung; Chung Mau Lo
Journal:  Hepatol Int       Date:  2018-02-15       Impact factor: 6.047

9.  Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Xiao-Wen Huang; Yang Huang; Li-da Chen; Zhu Wang; Zheng Yang; Jin-Ya Liu; Xiao-Yan Xie; Ming-De Lu; Shun-Li Shen; Wei Wang
Journal:  J Med Ultrason (2001)       Date:  2017-10-20       Impact factor: 1.314

10.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.